Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin
Executive Summary
Merck’s focus has shifted increasingly to Keytruda and immuno-oncology, while the company’s older stalwarts like Zetia, Vytorin and Januvia face pressure.
You may also be interested in...
Stockwatch: An Earnings Season Renaissance Fades
Big pharma companies like Novartis, Merck, Bristol-Myers Squibb and Eli Lilly tried to restore a semblance of positivity to third-quarter earnings season last week but a counter-current of detail in the results of Vertex, Amgen and Biogen gave other ideas.
Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch
Testing for the biomarker has picked up since paradigm changing data in first-line lung cancer was presented at ESMO, management said. Now, with the FDA approval of Keytruda, Merck is focused on establishing a solid lead in a big commercial market.
Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.